2-[(2-Chlorophenyl)-hydroxymethylidene]propanedinitrile | 1374858-65-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[(2-Chlorophenyl)-hydroxymethylidene]propanedinitrile
• 英文别名: 2-[(2-chlorophenyl)-hydroxymethylidene]propanedinitrile
• CAS: 1374858-65-7
• 化学式: C₁₀H₅ClN₂O
• 分子量: 204.615
• InChiKey: JSZXEXBEAQCLHP-UHFFFAOYSA-N

物化性质

• 沸点：
  331.6±42.0 °C(Predicted)
• 密度：
  1.398±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-[(2-Chlorophenyl)-hydroxymethylidene]propanedinitrile 在 ammonium hydroxide 、 硫酸 、 硫化氢 、 双氧水 、 三乙胺 、 三氯氧磷 作用下， 以 甲醇 、 苯 为溶剂， 反应 7.5h， 生成
  参考文献：
  名称：

  Isothiazole and isoxazole fused pyrimidones as PDE7 inhibitors: SAR and pharmacokinetic evaluation

  摘要：

  The synthesis and structure-activity relationship studies of isothiazole and isoxazole fused pyrimidones as PDE7 inhibitors are discussed. The pharmacokinetic profile of 10 and 21 with adequate CNS penetration, required for in vivo Parkinson's disease models, are disclosed. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.025
• 作为产物：
  描述：

  邻氯苯甲酰氯 、 丙二腈 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 生成 2-[(2-Chlorophenyl)-hydroxymethylidene]propanedinitrile
  参考文献：
  名称：

  Isothiazole and isoxazole fused pyrimidones as PDE7 inhibitors: SAR and pharmacokinetic evaluation

  摘要：

  The synthesis and structure-activity relationship studies of isothiazole and isoxazole fused pyrimidones as PDE7 inhibitors are discussed. The pharmacokinetic profile of 10 and 21 with adequate CNS penetration, required for in vivo Parkinson's disease models, are disclosed. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.03.025

文献信息

• Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines
  作者：Anna Lucia Fallacara、Raffaele Passannanti、Mattia Mori、Giulia Iovenitti、Francesca Musumeci、Chiara Greco、Emmanuele Crespan、Miroslava Kissova、Giovanni Maga、Chiara Tarantelli、Filippo Spriano、Eugenio Gaudio、Francesco Bertoni、Maurizio Botta、Silvia Schenone

  DOI：10.1016/j.ejmech.2019.07.048

  日期：2019.11

  Abnormal activation of B-cell receptor (BCR) signaling plays a key role in the development of lymphoid malignancies, and could be reverted by the simultaneous inhibition of Lyn, Fyn and Blk, three members of the Src family kinase (SFK).Fyn and Blk are also promising targets for the treatment of some forms of T-cell non-Hodgkin lymphoma which point to the druggability of SFKs for the treatment of these cancers. We recently identified Si308 as a potent Fyn inhibitor, while preliminary data showed that it might also inhibit Lyn and Blk. Here, molecular modelling studies were coupled with enzymatic assays to further investigate the effect of Si308 on Lyn and Blk. A small library of pyrazolo[3,4-d]pyrimidines structurally related to Si308 was synthesized and tested on human lymphoma cell lines. Compound 2h emerged as a new multitarget inhibitor of Lyn, Fyn and Blk endowed with remarkable antiproliferative effects on human B and T lymphoma cell lines. Its favorable ADME properties make the compound suitable for further developments. (C) 2019 Published by Elsevier Masson SAS.
• Isothiazole and isoxazole fused pyrimidones as PDE7 inhibitors: SAR and pharmacokinetic evaluation
  作者：Abhisek Banerjee、Pravin S. Yadav、Malini Bajpai、Ramachandra Rao Sangana、Srinivas Gullapalli、Girish S. Gudi、Laxmikant A. Gharat

  DOI：10.1016/j.bmcl.2012.03.025

  日期：2012.5

  The synthesis and structure-activity relationship studies of isothiazole and isoxazole fused pyrimidones as PDE7 inhibitors are discussed. The pharmacokinetic profile of 10 and 21 with adequate CNS penetration, required for in vivo Parkinson's disease models, are disclosed. (C) 2012 Elsevier Ltd. All rights reserved.